Search results for #AAN2024
At AAN 2024, @AlexionPharma and @AstraZeneca Rare Disease presented interim analysis findings from the ongoing Phase III CHAMPION-NMOSD trial (NCT04201262). To know more about NMOSD treatment landscape, visit: tinyurl.com/mryy95ew #AAN2024 #Alexion #AstraZeneca #NMOSD
Take advantage of our conference offers for American Academy of Neurology Annual Meeting Conference until 19th May. Apply code 101999 at checkout. #AAN2024 cup.org/3UP69SJ
At AAN 2024, significant findings were unveiled regarding the efficacy and safety of Ocrelizumab in the treatment of multiple sclerosis. Read more: tinyurl.com/j3npf772 #AAN2024 #Ocrelizumab #MultipleSclerosis #NeurologyConference #ENSEMBLEtrial #OCARINAII #MSresearch
At AAN 2024, @EisaiUS unveiled groundbreaking research on DAYVIGO (lemborexant), demonstrating its effectiveness in addressing insomnia-related concerns. For more: tinyurl.com/44sjex3d #AAN2024 #EisaiInc #DAYVIGO #Lemborexant #InsomniaTreatment #NeurologyConference
At AAN 2024, @biohaven presented abstracts detailing the characterization of their lead candidate within the Kv7 platform, BHV-7000, as a potential treatment for seizures. Explore more about the Epilepsy treatment market @ tinyurl.com/z7e4usz4 #AAN2024 #Biohaven #BHV7000
At AAN 2024, data from the ongoing Phase II FENopta study (NCT05119569) underscored the effectiveness and safety of fenebrutinib, a potent Bruton’s tyrosine kinase (BTK) inhibitor, in treating relapsing Multiple Sclerosis. For more: tinyurl.com/748uwhxz #AAN2024 #FENopta
During the AAN 2024, @sanofi presented fresh 48-week data from the Phase II trial (NCT04879628) of Frexalimab, highlighting its potential for sustained efficacy in treating multiple sclerosis. For more: tinyurl.com/5zhf7shd #Sanofi #Frexalimab #MultipleSclerosis #AAN2024
Thank you to all who stopped by our booth or a Praxis presentation at #AAN2024! Our #AANAM participation highlighted our commitment to advancing therapies for CNS disorders, including #EssentialTremor. Click here for the latest updates & resources: praxismedicines.com
Congratulations to our CHeT Outcomes team for their outstanding presentations at the AAN Annual Meeting in Denver! Their impactful research is shaping the future of neurology. #AAN2024 #Neurology #research Learn more about CHeT Outcomes: tinyurl.com/26canpmk
With Prof. Mohammed Wasay Chairman, Advocacy and Awareness Task Force of World Federation of Neurology @wfneurology the Recipient of Kenneth Viste of Patient Advocate Award of the year 2024 of the American Academy of Neurology @AANmember at #AAN2024 - M.A.Aleem Neurologist India
With José Biller an author for the book "Localization in Clinical Neurology" at #AAN2024 - M.A.Aleem Neurologist #Trichy #TamilNadu #India
#AAN2024: Compared with oral LD/CD, subcutaneous LDP/CDP led to improved time with symptom control in patients with advanced #Parkinsondisease. ➡️brnw.ch/21wJ8tp @AANmember #NeuroTwitter
#AAN2024: Adult patients with treatment-resistant #epilepsy experienced a reduction in #seizures with add-on CBD treatment. ➡️brnw.ch/21wJ89U @AANmember #NeuroTwitter
Who else was at American Academy of Neurology #AAN2024? Our team loved connecting with other scientists, physicians, and healthcare leaders last week, and is feeling more inspired than ever about the work we do. #multiplesclerosis #neuroscience #ms #msresearch
Subcutaneous Ocrevus can help adults with MS remain free of clinical relapses and new or worsening brain lesions, trial data show. bit.ly/3UuMxmp #aan2024 #MS #MultipleSclerosis #MSResearch #MSNews #MSTreatment #ClinicalTrial
We had a fantastic time at the @AANmember 2024 Annual Meeting! We’re excited to keep advancing #science and improving the lives of those with #neurological disorders. To learn more about the information we presented, visit: bit.ly/3weSbj0 #AAN2024 #BeBiohaven
#AAN2024: Treatment optimization for patients with #migraine was considered “poor” with more than 11% discontinuing #triptans. ➡️brnw.ch/21wJ5Tk @AANmember #NeuroTwitter
#AAN2024: Treatment with #fremanezumab over a 6-month period was effective and well-tolerated in patients with both #migraine and #obesity. ➡️brnw.ch/21wJ5AG @AANmember #NeuroTwitter
#AAN2024: Compared with placebo, #vutrisiran therapy led to improved neurologic function and quality of life in patients with hATTR amyloidosis with #polyneuropathy. ➡️brnw.ch/21wJ5rF @AANmember #NeuroTwitter
#AAN2024: Compared with placebo, #dextromethorphanbupropion increased time to relapse for agitation symptoms in patients with #Alzheimerdisease. ➡️brnw.ch/21wJ5kS @AANmember #NeuroTwitter
